glp-1 receptor agonist atrial fibrillation risk Association of glucagon-like peptide-1 agonists with fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization | Diabetology & Metabolic Syndrome GLP-1 RAs demonstrate rhythm-protective benefits

13,14,15 By integrating the latest clinical trial data, we explore the efficacy of GLP-1RAs in treating diseases of the nervous, cardiovascular, endocrine, and digestive systems

This distribution suggests GIP influences metabolism through somewhat different pathways than GLP-1, even though both are incretin hormones

Compounded gallbladder motility results in sludge accumulation and gallstone development [46]

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 17 trials

(2021, June 4)

Consistent with this, plasma levels of GLP-1 rapidly increase in healthy humans upon direct administration of carbohydrates or lipids into the ileum [210]